Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20109207 | 0.84 | CYP2C19 (0.32) | CYP2C19ALDH1A1KDM4EUSP2ALOX15 | |
| SCHEMBL20109131 | 0.84 | CYP2C19 (0.35) | CYP2C19ALDH1A1MAPTKDM4EUSP2 | |
| SCHEMBL20109242 | 0.82 | HSD17B10 (0.42) | TSHR | |
| SCHEMBL20109243 | 0.81 | SIGMAR1 (0.32) | ALDH1A1KDM4EALOX15TSHR | |
| SCHEMBL20113534 | 0.78 | OPRD1 (0.36) | ALDH1A1GAAMAPTTSHR | |
| SCHEMBL20109250 | 0.77 | CYP2D6 (0.36) | ALDH1A1KDM4E | |
| SCHEMBL20109256 | 0.75 | ALDH1A1 (0.41) | ALDH1A1GAAMAPTTSHRSMN1; SMN2 | |
| SCHEMBL20113538 | 0.74 | ALDH1A1 (0.39) | ALDH1A1GAAMAPTTSHRSMN1; SMN2 | |
| SCHEMBL20109240 | 0.72 | CHRNA7 (0.36) | MAPTALOX15 | |
| SCHEMBL20109238 | 0.69 | TRPA1 (0.32) | ALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118770-A1 | N-Heterocyclic Phosphines | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118770-A1 | N-Heterocyclic Phosphines | NANP, PPIP5K2, PHPT1 | CYP2C19 2738/4885ALDH1A1 4621/4885TP53 1611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.